PrEPWatch Logo
An Initiative of AVAC
  • About PrEP
    • The Basics
    • About Oral PrEP
    • Evidence & Research for Oral PrEP
    • About the Dapivirine Ring
    • Evidence & Research for the Dapivirine Ring
  • PrEP Planning A-Z
    • PrEP Communications Accelerator
    • OPTIONS Plan 4 PrEP Toolkit
    • Policies, Plans and Budgets
    • Supply Chain Management
    • Delivery Issues & Best Practices
    • Promoting Demand & Uptake Adherence
    • Monitoring & Evaluation
  • In Practice
    • Implementation Initiatives and Partners
    • Lessons from the Field
    • Global PrEP Tracker
    • Country Updates
    • Virtual Learning Network
    • West Africa Regional PrEP Learning Network
  • Resources
  • Next-Gen
    • Long Acting Injectables
    • The Dual Prevention Pill
    • Research Pipeline
  • About PrEP
    • The Basics
    • About Oral PrEP
    • Evidence & Research for Oral PrEP
    • About the Dapivirine Ring
    • Evidence & Research for the Dapivirine Ring
  • PrEP Planning A-Z
    • PrEP Communications Accelerator
    • OPTIONS Plan 4 PrEP Toolkit
    • Policies, Plans and Budgets
    • Supply Chain Management
    • Delivery Issues & Best Practices
    • Promoting Demand & Uptake Adherence
    • Monitoring & Evaluation
  • In Practice
    • Implementation Initiatives and Partners
    • Lessons from the Field
    • Global PrEP Tracker
    • Country Updates
    • Virtual Learning Network
    • West Africa Regional PrEP Learning Network
  • Resources
  • Next-Gen
    • Long Acting Injectables
    • The Dual Prevention Pill
    • Research Pipeline
  • Home
  • In Practice
  • Country Updates

Country Updates

This page offers a look at PrEP access nation-by-nation via individual country pages:

  • Australia
  • Austria
  • Bahamas
  • Barbados
  • Belgium
  • Benin
  • Botswana
  • Brazil
  • Burkina Faso
  • Canada
  • Cameroon
  • Chile
  • China
  • Côte d’Ivoire
  • Croatia
  • Cuba
  • Czech Republic
  • Democratic Republic of Congo
  • Denmark
  • Dominican Republic
  • Ecuador
  • Eritrea
  • Eswatini
  • Ethiopia
  • Finland
  • France
  • Georgia
  • Germany
  • Ghana
  • Greece
  • Guatemala
  • Haiti
  • Iceland
  • India
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Kenya
  • Laos
  • Lesotho
  • Luxembourg
  • Malawi
  • Malaysia
  • Mali
  • Mexico
  • Morocco
  • Mozambique
  • Namibia
  • Nepal
  • Netherlands
  • New Zealand
  • Nigeria
  • Norway
  • Pakistan
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Rwanda
  • Senegal
  • Slovenia
  • Sri Lanka
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Tanzania
  • Thailand
  • Togo
  • Uganda
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam
  • Zambia
  • Zimbabwe
PrEP Watch is a one-stop for PrEP data, research, cost, access, implementation and advocacy efforts across the globe. Learn more about PrEP
Connect with us
Email
Facebook
Twitter
  • About PrEP
    • The Basics
    • About Oral PrEP
    • Evidence & Research for Oral PrEP
    • About the Dapivirine Ring
    • Evidence & Research for the Dapivirine Ring
  • PrEP Planning A-Z
    • PrEP Communications Accelerator
    • OPTIONS Plan 4 PrEP Toolkit
    • Policies, Plans and Budgets
    • Supply Chain Management
    • Delivery Issues & Best Practices
    • Promoting Demand & Uptake Adherence
    • Monitoring & Evaluation
  • In Practice
    • Implementation Initiatives and Partners
    • Lessons from the Field
    • Global PrEP Tracker
    • Country Updates
    • Virtual Learning Network
    • West Africa Regional PrEP Learning Network
  • Resources
  • Next-Gen
    • Long Acting Injectables
    • The Dual Prevention Pill
    • Research Pipeline
PrEP Communications Accelerator
OPTIONS Accelerator
Fast tracking PrEP uptake through strategic communications and demand creation. Get started!
AVAC

PrEP Watch was created and is maintained by AVAC, a non-profit organization based in New York that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of new and emerging HIV prevention options as part of a comprehensive response to the HIV/AIDS pandemic. AVAC receives no money from pharmaceutical companies, including Gilead Sciences. If you have a comment or suggestion regarding the content of this site, click here to contact us. Read our privacy policy.